NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Descending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
42658-0021-92 | 42658-0021 | Daunorubicin hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 19, 2022 | In Use | |
42658-0021-91 | 42658-0021 | Daunorubicin hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 15, 2023 | In Use | |
00409-0004-04 | 00409-0004 | PEMETREXED | PEMETREXED | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00409-0020-02 | 00409-0020 | PEMETREXED | PEMETREXED | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00409-0021-03 | 00409-0021 | PEMETREXED | PEMETREXED | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00527-1242-02 | 00527-1242 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec. 31, 2019 | In Use | |
25021-0226-10 | 25021-0226 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb. 15, 2023 | In Use | |
25021-0227-06 | 25021-0227 | Arsenic Trioxide | Arsenic Trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb. 15, 2023 | In Use | |
46708-0678-02 | 46708-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 28, 2023 | In Use | |
46708-0678-08 | 46708-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 28, 2023 | In Use |
Found 10,000 results in 9 milliseconds — Export these results